---
title: "Cadrenal Maintained at Buy as Partnership-Focused Strategy Supports Unchanged $13 Price Target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295921070.md"
description: "H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Cadrenal Therapeutics with an unchanged $13 price target. The decision reflects confidence in the company's partnership-focused strategy, including out-licensing and non-dilutive funding, which supports key programs like CAD-1005 and tecarfarin while conserving capital. Although current cash only covers operations into 1Q27, successful execution of partnering strategies is expected to unlock shareholder value."
datetime: "2026-08-14T10:26:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295921070.md)
  - [en](https://longbridge.com/en/news/295921070.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295921070.md)
generator: "portal-rs"
---

# Cadrenal Maintained at Buy as Partnership-Focused Strategy Supports Unchanged $13 Price Target

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Cadrenal Therapeutics, Inc., retaining the price target of $13.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Joseph Pantginis has given his Buy rating due to a combination of factors, including Cadrenal’s deliberate shift toward a partnership-focused business model that aligns with its limited capital resources. By emphasizing out-licensing, co-development, and non-dilutive funding, the company can continue advancing key programs such as CAD-1005, frunexian, and tecarfarin while reducing reliance on dilutive equity offerings.

He also highlights management’s ongoing efforts to secure strategic partners and regulatory designations, such as the Rare Pediatric Disease request for tecarfarin, as important catalysts for value creation. Although current cash only funds operations into 1Q27 and is insufficient to independently carry programs through late-stage trials, the unchanged $13 price target reflects his view that successful execution of partnering and grant strategies can unlock meaningful upside for shareholders.

### Related Stocks

- [CVKD.US](https://longbridge.com/en/quote/CVKD.US.md)

## Related News & Research

- [Cadrenal Therapeutics CEO presents at H.C. Wainwright Global Investment Conference](https://longbridge.com/en/news/297910480.md)
- [Apalach Current Reaches 2,000 Subscribers as Independent Newsletter Expands Coverage of Florida’s Forgotten Coast](https://longbridge.com/en/news/298468032.md)
- [Saga Communications declares quarterly cash dividend of $0.25 a share](https://longbridge.com/en/news/298639640.md)
- [REG - State Street Global Gamma Communications - Form 8.3 - Gamma Communications plc](https://longbridge.com/en/news/298331080.md)
- [CCOI Deadline Alert: SueWallSt Reminds COGENT COMMUNICATIONS HOLDINGS, INC. (CCOI) Investors of Securities Class Action Deadline on September 21, 2026](https://longbridge.com/en/news/298609919.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**